Paper38201624
Atezolizumab and Bevacizumab Combination Therapy in the Treatment of Advanced Hepatocellular Cancer.
Ventura I and 4 others. Cancers (Basel), 2023. Cited by 13 papers, by iCite.
Cite this record
ConductScience Library. Atezolizumab and Bevacizumab Combination Therapy in the Treatment of Advanced Hepatocellular Cancer. Papers, record 38201624. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38201624
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Atezolizumab and Bevacizumab Combination Therapy in the Treatment of Advanced Hepatocellular Cancer.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References38
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 31718044 | TGF-β in Hepatic Stellate Cell Activation and Liver Fibrogenesis-Updated 2019. | Cells | 2019 | https://conductscience.org/library/papers/31718044 | PubMed |
| 2 | 33090190 | The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma: A Review. | JAMA Oncol | 2021 | https://conductscience.org/library/papers/33090190 | PubMed |
| 3 | 35626046 | Cancer Survival in Adults in Spain: A Population-Based Study of the Spanish Network of Cancer Registries (REDECAN). | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/35626046 | PubMed |
| 4 | 19621070 | The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. | PLoS Med | 2009 | https://conductscience.org/library/papers/19621070 | PubMed |
| 5 | 21829019 | Molecular pathogenesis of hepatocellular carcinoma: altering transforming growth factor-β signaling in hepatocarcinogenesis. | Dig Dis | 2011 | https://conductscience.org/library/papers/21829019 | PubMed |
| 6 | 31439937 | A global view of hepatocellular carcinoma: trends, risk, prevention and management. | Nat Rev Gastroenterol Hepatol | 2019 | https://conductscience.org/library/papers/31439937 | PubMed |
| 7 | 31371809 | Insights into the success and failure of systemic therapy for hepatocellular carcinoma. | Nat Rev Gastroenterol Hepatol | 2019 | https://conductscience.org/library/papers/31371809 | PubMed |
| 8 | 33781993 | PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. | BMJ | 2021 | https://conductscience.org/library/papers/33781993 | PubMed |
| 9 | 30875085 | Cancer screening in the United States, 2019: A review of current American Cancer Society guidelines and current issues in cancer screening. | CA Cancer J Clin | 2019 | https://conductscience.org/library/papers/30875085 | PubMed |
| 10 | 36482887 | Identification of subtypes of hepatocellular carcinoma and screening of prognostic molecular diagnostic markers based on cell adhesion molecule related genes. | Front Genet | 2022 | https://conductscience.org/library/papers/36482887 | PubMed |
| 11 | 34902530 | Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. | J Hepatol | 2022 | https://conductscience.org/library/papers/34902530 | PubMed |
| 12 | 34424422 | Immunotherapy in Hepatocellular Carcinoma. | Curr Treat Options Oncol | 2021 | https://conductscience.org/library/papers/34424422 | PubMed |
| 13 | 36727247 | The revised JBI critical appraisal tool for the assessment of risk of bias for randomized controlled trials. | JBI Evid Synth | 2023 | https://conductscience.org/library/papers/36727247 | PubMed |
| 14 | 25173969 | Lack of arterial hypervascularity at contrast-enhanced ultrasound should not define the priority for diagnostic work-up of nodules <2 cm. | J Hepatol | 2015 | https://conductscience.org/library/papers/25173969 | PubMed |
| 15 | 33538338 | Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. | CA Cancer J Clin | 2021 | https://conductscience.org/library/papers/33538338 | PubMed |
| 16 | 32710922 | Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma. | J Hepatol | 2020 | https://conductscience.org/library/papers/32710922 | PubMed |
| 17 | 36148739 | Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study. | Eur J Cancer | 2022 | https://conductscience.org/library/papers/36148739 | PubMed |
| 18 | 22992590 | TGFβ signalling in context. | Nat Rev Mol Cell Biol | 2012 | https://conductscience.org/library/papers/22992590 | PubMed |
| 19 | 31830641 | Current strategies for the treatment of intermediate and advanced hepatocellular carcinoma. | Cancer Treat Rev | 2020 | https://conductscience.org/library/papers/31830641 | PubMed |
| 20 | 33007432 | Immunotherapy for advanced hepatocellular carcinoma, where are we? | Biochim Biophys Acta Rev Cancer | 2020 | https://conductscience.org/library/papers/33007432 | PubMed |
Cited by12
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 13 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42353339 | Deubiquitinating Enzymes as Therapeutic Candidates in Hepatocellular Carcinoma and Other Liver Disease. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42353339 | PubMed |
| 42272946 | Current Therapeutic Strategies, Recent Advances and the Emerging Potential of Natural Products in Hepatocellular Carcinoma. | Scientifica (Cairo) | 2026 | https://conductscience.org/library/papers/42272946 | PubMed |
| 41804306 | Endoscopic Innovation Treatment Strategy in Hepatocellular Carcinoma (HCC) Patients Before Immunotherapy: A Case Series Study in Unselected Patients. | JGH Open | 2026 | https://conductscience.org/library/papers/41804306 | PubMed |
| 41796277 | Serum biomarkers as personalised medicine for diagnostic and therapeutic approaches of hepatocellular carcinoma. | J Egypt Natl Canc Inst | 2026 | https://conductscience.org/library/papers/41796277 | PubMed |
| 40950361 | Mechanistic insights into the anti-tumor effects of neochlorogenic acid in hepatocellular carcinoma: in vitro and in vivo studies. | J Gastrointest Oncol | 2025 | https://conductscience.org/library/papers/40950361 | PubMed |
| 40928680 | Quantum chemical optimization and residue-specific stabilization of CDK20 inhibitors in hepatocellular carcinoma. | Mol Divers | 2026 | https://conductscience.org/library/papers/40928680 | PubMed |
| 40445470 | Modern therapeutic approaches for hepatic tumors: progress, limitations, and future directions. | Discov Oncol | 2025 | https://conductscience.org/library/papers/40445470 | PubMed |
| 40395491 | Atezolizumab Plus Bevacizumab Combined with or without Transarterial Chemoembolization in the Treatment of Advanced Hepatocellular Carcinoma: A Single-Center Retrospective Study. | J Hepatocell Carcinoma | 2025 | https://conductscience.org/library/papers/40395491 | PubMed |
| 40144486 | Atezolizumab and bevacizumab combination in advanced hepatocellular carcinoma patients: The imperative for safety assessment studies. | World J Clin Cases | 2025 | https://conductscience.org/library/papers/40144486 | PubMed |
| 40061962 | Adverse drug reactions to atezolizumab in combination with bevacizumab in hepatocellular carcinoma patients: an analysis of the food and drug administration adverse event reporting system database. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/40061962 | PubMed |
| 40010999 | Effect of Nutritional Index on Lenvatinib Treatment Retention Rates in Unresectable Hepatocellular Carcinoma. | In Vivo | 2025 | https://conductscience.org/library/papers/40010999 | PubMed |
| 38398229 | Outcome of Atezolizumab Plus Bevacizumab Combination Therapy in High-Risk Patients with Advanced Hepatocellular Carcinoma. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/38398229 | PubMed |
Genes5
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| AFP | 174 | PubTator's text mining | https://conductscience.org/library/genes/174 | NCBI Gene |
| ALB | 213 | PubTator's text mining | https://conductscience.org/library/genes/213 | NCBI Gene |
| CD274 | 29126 | PubTator's text mining | https://conductscience.org/library/genes/29126 | NCBI Gene |
| TGFB1 | 7040 | PubTator's text mining | https://conductscience.org/library/genes/7040 | NCBI Gene |
| VEGFA | 7422 | PubTator's text mining | https://conductscience.org/library/genes/7422 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/38201624
GET https://conductscience.org/api/papers/v1/38201624/references?page=2